Kolltan Pharmaceuticals aims to price initial public offering of stock

Leerink, Stifel are bookrunners; Guggenheim, Janney Montgomery assist

By Devika Patel

Knoxville, Tenn., Sept. 12 – Kolltan Pharmaceuticals, Inc. will conduct an initial public sale of its common stock with a 30-day greenshoe option, according to a Form S-1 filed Friday with the Securities and Exchange Commission.

Leerink Partners and Stifel are the joint bookrunning managers. Guggenheim Securities and Janney Montgomery Scott are the co-managers.

Proceeds will be used for clinical development, advancement of product candidates, research programs, preclinical research to select additional development candidates, working capital and other general corporate purposes.

The clinical-stage biopharmaceutical company is based in New Haven, Conn. It intends to list its common stock on the Nasdaq under the symbol “KLTN.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.